Committee Connection
  • Neoadjuvant Therapy for Resectable Pancreatic Cancer

    25 Feb 2014 08:05 PM

    Introduction     By Sabha Ganai, MD, PhD Southern Illinois University School of Medicine Pancreatic adenocarcinoma is currently the fourth leading cause of cancer death in the United States, with five-year survival rates for patients with localized disease remaining under 25%.1 Despite improvements in morbidity and mortality from pancreas surgery, as well as a greater focus on preoperative imaging and staging prior... Read more

  • Immunotherapy for Prostate Cancer: Past, Present, and Future

    16 Dec 2013 04:27 PM

    By L. Michael Glodé, MD, FASCO University of Colorado, Denver   The field of immunotherapy for cancer has a long and complex history. Although there are reports of a relationship between infection and tumor regression dating to the 18th century, William Coley, MD, is often credited with being the “father of immunotherapy.” Ultimately, as head of the Bone Tumor Service at Memorial Hospital in New York, he injected over one... Read more

  • Adjuvant Chemotherapy for Patients with Stage II Colon Cancer: Considerations for Medical and Surgical Oncologists

    28 Oct 2013 08:53 PM

    Introduction By Stephen Leong, MD University of Colorado Cancer Center   It is estimated that more than 102,000 new colon cancer cases will be diagnosed in the United States this year.1 Approximately 40% of these will be classified as localized (stage I and stage II).1 The five-year survival estimates for patients with stage II colon cancer vary widely. According to the American Joint Committee on Cancer (AJCC; Surveillance,... Read more

  • Is Radioactive Iodine Overused in Thyroid Cancer Treatment?

    22 Aug 2013 03:54 PM

    IntroductionBy Karen M. Devon, MD, MSc, FRCSC University of Toronto  In 1923, Henry Plummer at Mayo Clinic first observed that iodine immediately after thyroid operation calmed the patient and hastened recovery.1 Since then, radioactive iodine was developed to treat Graves’ disease, and subsequently indications extended to thyroid cancer. Despite the very favorable outcomes associated with differentiated thyroid cancer, radioactive iodine... Read more

  • A Growing Need for Multidisciplinary Treatment for Genitourinary Cancers

    25 Jun 2013 02:28 PM

    Evidence suggests indications for medical and radiation oncology evaluations pre- and post-surgery   Erik P. Castle, MDIntroductionBy Erik P. Castle, MD Mayo Clinic ArizonaThe incorporation of neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer is a complex and often controversial issue. Despite the available level 1 evidence supporting neoadjuvant chemotherapy, its use is still surprisingly low.1,2... Read more

  • Tissue Acquisition for Personalized Therapy: Merits and Drawbacks

    22 Apr 2013 02:46 PM

    IntroductionBy Al B. Benson III, MD, FACP, FASCOFeinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern UniversityPersonalized medicine embodies the concept of delivering the right care at the right time. An individualized approach to provide value-based, high-quality cancer care incorporates team medicine requiring patient access to comprehensive services offered by nurses, multispecialty oncology clinicians,... Read more